Our results are consistent with those of Miranda et al. [58] and Yu et al. [59] who confirmed the overexpression of the c-Met in lung cancer (adenocarcinoma and squamous cell carcinoma), and it was highly expressed in 61% of NSCLCs. The gene discussed is MET; the disease is lung carcinoma.